Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users

@article{Quinn1997PharmacokineticAP,
  title={Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users},
  author={David I. Quinn and Alex D Wodak and Richard Osborne Day},
  journal={Clinical Pharmacokinetics},
  year={1997},
  volume={33},
  pages={344-400}
}
SummaryMany clinicians are confronted by the use of illicit drugs on a daily basis. The unsanctioned use of opioids, psychostimulants, benzodiazepines, alcohol and nicotine is a major cause of morbidity and mortality. Multiple factors have inhibited the scientific study of these agents including prohibition, public denial and lack of commercial interests. In dealing with problems related to these drugs, clinicians need a scientific understanding of their pharmacology, quantifiable effects and… 
Pharmacodynamic Evaluation : Drug Dependency and Addiction
TLDR
This review presents the current knowledge on the pharmacodynamic profile of the most common illicit and recreational drugs and its influence on drug dependency and addiction and suggests some ideas for future observation and research.
The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.
TLDR
It is anticipated that pharmacogenetics will be used to identify individuals at a greater risk for specific drug dependencies, provide information that can lead to novel treatment and prevention approaches as well as provide guidance for individualization of treatment choice.
The effects of methadone and its role in fatalities
TLDR
An overview of the chief effects of methadone on the human body is presented, considering its metabolism, drug interactions and tolerance, and some basic information is provided for those dealing with individuals who have consumed Methadone.
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
TLDR
Several interactions between methadone, buprenorphine, or naltrexone and psychoactive medications are described and may have important clinical consequences and clinicians must be alerted to these interactions.
INTERACTIONS BETWEEN DRUGS OF ABUSE AND HIV PROTEASE INHIBITORS
TLDR
Achieving target in tracellular concentrations during long term therapy of several diseases can be challenging due to number of factors such as poor adherence, drug resistance and drug-drug interactio ns.
Neurobiology, pharmacokinetics and pharmacodynamics of drug abuse
TLDR
The pharmacokinetic properties of a drug that dispose the user to increased self-administration include rapid absorption, rapid entry into the central nervous system, high bioavailability, short half-life, small volume of distribution, and high free drug clearance.
Interindividual Variability of the Clinical Pharmacokinetics of Methadone
TLDR
Because of the high morbidity and mortality associated with opioid dependence, it is of major importance that methadone is used at an effective dosage in maintenance treatment: at least 60 mg/day, but typically 80–100 mg/ day.
Clinical Pharmacokinetics of Amfetamine and Related Substances
TLDR
Because of the physicochemical properties of amfetamine-type stimulants, this group of drugs is one of the most suitable for drug testing in non-conventional matrices and has recently gained much attention because of its possible applications in clinical and forensic toxicology.
Relative addictive potential of opioid analgesic agents.
TLDR
Providers should consider the risk of addiction with the opioids they prescribe and give those with a lower addictive potential a chance of survival.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 533 REFERENCES
Clinical Pharmacokinetics of Non-Opiate Abused Drugs
TLDR
The clinical significance of kinetic characteristics with respect to abuse is discussed where possible and the pharmacokinetic properties that presumably contribute to self-administration and drug abuse include rapid delivery of the drug into the central nervous system and high free drug clearance.
Pharmacokinetic Determinants of Drug Abuse and Dependence
SummaryDrugs that produce physical dependence or have similar pharmacological profiles to highly abused drugs are unlikely to be considered acceptable for marketing. Thus, the prediction of abuse and
Drug Interactions of Clinical Significance with Opioid Analgesics
TLDR
The knowledge of particular opioid-drug interactions, and the causative pharmacokinetic, pharmacodynamic, and idiosyncratic mechanisms, allows for the safer administration of opioid analgesics.
Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
TLDR
Clinical trials on the use of the opioid antagonist, naltrexone, to reduce alcohol's pleasurable effects and enhance the effectiveness of psychosocial therapy showed reduced rates of alcohol relapse, number of drinking days and alcohol craving.
Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain
TLDR
The results suggest that only the free (unbound) fraction of methadone present in blood is extracted by the liver and that methdone can be classified as a low (hepatic)‐extraction drug.
'Horse trading': prescribing injectable opiates to opiate addicts. A descriptive study.
TLDR
The clinical audit of 40 opiate-dependent individuals who were prescribed injectable drugs (heroin or methadone) between June 1987 and June 1989 is described to attract entrenched injectors into contact with treatment services and to promote movement away from injecting drug use and reduce HIV risk behaviour.
DISPOSITION OF NARCOTICS AND NARCOTIC ANTAGONISTS *
  • C. Inturrisi
  • Medicine
    Annals of the New York Academy of Sciences
  • 1976
TLDR
This paper reviews recent information on the disposition of methadone, alpha-I-acetylmethado1.t and naltrexone in relation to the possible contribution of active metabolites to certain of the pharmacological effects of these drugs in man.
Pharmacological options for management of opioid dependence.
TLDR
Alternative opioids include long-acting partial agonists such as buprenorphine and pure antagonists such as naltrexone and non-opioid adjuncts such as alpha2-adrenoceptor agonists, which might be of use for specific groups of opioid users, providing therapists with the flexibility to tailor pharmacotherapy to the individual needs of clients.
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
TLDR
Despite the overall high attrition rates from trials, in selected patient groups and in combination with appropriate support mechanisms and psychotherapy, naltrexone represents a useful adjunct for the maintenance of abstinence in the detoxified opioid addict.
Clinical Pharmacokinetics of Clonidine
TLDR
Clonidine is a centrally active antihypertensive agent effective in the treatment of mild, moderate and severe hypertension, alone or in combination with other drugs, and once weekly transdermal clonidine dosing offers the potential for improved patient compliance.
...
1
2
3
4
5
...